Companies that use Veeva

Source: Analysis of 100 job postings that mention Veeva

My analysis shows Veeva buyers span commercial, regulatory, quality, and medical affairs leadership. Commercial Operations Directors (18%) and Associate Directors of Medical Science Liaison teams (12%) lead purchasing decisions, alongside Quality Assurance Directors (10%) and Regulatory Affairs Directors (9%). These leaders prioritize digital transformation, compliance automation, and connecting fragmented data systems. Their job descriptions emphasize building scalable platforms that span CRM, document management, and analytics to drive speed to market while maintaining regulatory rigor.

Day-to-day users are predominantly field-based medical affairs professionals, regulatory specialists, quality engineers, and commercial analysts. Medical Science Liaisons use Veeva for documenting healthcare provider interactions and capturing insights, while regulatory teams manage submission workflows and documentation. Quality professionals leverage it for audit readiness and CAPA tracking. Commercial teams rely on Veeva for sales force effectiveness, territory alignment, incentive compensation, and customer targeting. Many postings mention hands-on CRM data management, report generation, and cross-functional coordination as core activities.

The pain points reveal a need for operational efficiency and audit readiness. Companies seek professionals who can ensure conformance to domestic and international quality regulations and GCP guidelines, drive operational excellence across brand initiatives, and maintain accurate, compliant documentation. Multiple postings emphasize delivering clinical milestones on time with quality and ensuring seamless coordination between internal teams and external partners. The recurring themes are speed, compliance, data integrity, and the ability to translate strategic priorities into executable plans across complex life sciences organizations.

Source: Analysis of tech stacks from 610 companies that use Veeva

I noticed that Veeva Vault users are overwhelmingly life sciences companies, specifically those in pharmaceuticals, biotechnology, and clinical research. The presence of Medidata Rave and eClinical Solutions, which are clinical trial management platforms, tells me these companies are running complex drug development programs that require strict regulatory compliance and document control throughout the product lifecycle.

The pairing of Veeva Vault with Medidata Rave makes perfect sense because clinical trials generate enormous volumes of regulated documents, from study protocols to patient consent forms to final study reports. These companies need both the trial data management that Medidata provides and the document lifecycle management that Veeva offers. Benchling's presence is particularly interesting because it's a platform for R&D data management, suggesting these companies are managing everything from early research through commercialization. Mastercontrol appearing so frequently reinforces the quality management theme, as it handles processes like deviations, complaints, and corrective actions that pharmaceutical companies must track meticulously.

The full stack reveals companies that are heavily regulated and process-driven rather than marketing-led or product-led in the traditional SaaS sense. These are organizations moving through long development cycles, often 10-plus years from discovery to market. They're likely mid-stage to mature companies with substantial funding, since implementing this suite of enterprise tools requires both budget and organizational maturity. The presence of Smartsheet alongside enterprise platforms suggests they're balancing formal compliance needs with day-to-day project management flexibility.

Source: Analysis of Linkedin bios of 610 companies that use Veeva

I noticed that Veeva Vault's typical customer operates in highly regulated life sciences sectors, primarily pharmaceutical manufacturing, biotechnology research, and medical device companies. These companies are actively developing, manufacturing, and commercializing therapeutic products ranging from small molecule drugs and biologics to antibody-drug conjugates, cell therapies, and diagnostic tools. They're not just conducting research, they're moving products through clinical trials and bringing them to market globally.

The companies span a remarkable range of maturity stages. I see clinical-stage biotechs with 11-50 employees alongside pharmaceutical giants like Pfizer, Novartis, and AstraZeneca with over 70,000 employees. However, the sweet spot appears to be growth-stage companies, either Series B through D funded biotechs or post-IPO commercial-stage firms with 50-500 employees. These companies are transitioning from pure research into clinical development and commercialization, which is precisely when regulatory compliance and documentation systems become critical.